Beta Drugs Limited is a pharmaceutical formulation manufacturing company that specializes in the development, manufacturing, and marketing of drug products for both domestic and international customers. The company primarily focuses on oncology products, including anti-cancer tablets, capsules, injections, and lyophilized injections. Company has a portfolio of over 50 products that are used for the treatment of various cancer diseases.
Founded in 1985, and is a part of the Adley Group and has its manufacturing unit located in Solan, Himachal Pradesh. With a focus on oncology products, the company is well-positioned to benefit from the growing demand for cancer treatment in India and abroad. As the global cancer drug market is projected to grow substantially in the coming years, Beta Drugs Limited is expected to see continued demand for its products and expand its reach in both the domestic and international markets.
Beta Drugs IPO Details
| IPO Date | Sep 29, 2017, to Oct 4, 2017 |
| Listing Date | Oct 12, 2017 |
| Face Value | ₹10 per share |
| Price | ₹85 per share |
| Lot Size | 1600 Shares |
| Total Issue Size | 2,296,000 shares (aggregating up to ₹19.52 Cr) |
| Issue Type | Fixed Price Issue IPO |
| Listing At | NSE SME |
Beta Drugs IPO Listing Details
| Listing Date | Oct 12, 2017 |
| BSE Script Code | |
| NSE Symbol | BETA |
| ISIN | INE351Y01019 |
| Final Issue Price | ₹85 per share |
Industry Overview
The pharmaceutical industry in India has been growing at a steady pace, and Beta Drugs Limited, being a part of this industry, is also expected to grow in the coming years. The oncology drug market in India is projected to grow significantly, with an increasing prevalence of cancer and rising healthcare expenditure. This presents a huge opportunity for Beta Drugs Limited to expand its market share and increase its revenue.
The Indian pharmaceutical industry is expected to grow at a CAGR of 11% from 2020 to 2026, driven by factors such as increasing healthcare awareness, rising disposable incomes, and the government’s focus on promoting the domestic pharmaceutical industry. The oncology segment is expected to grow at an even higher CAGR, driven by factors such as an aging population, lifestyle changes, and the increasing burden of cancer. As Beta Drugs Limited primarily focuses on oncology products, the company is well-positioned to benefit from this growth trend in the industry. Overall, the outlook for Beta Drugs Limited and the pharmaceutical industry in India is positive, with ample opportunities for growth in the coming years.
Company Financials
| Beta Drugs’ financial performance (in INR lakh) | ||||||
| FY2013 | FY2014 | FY2015 | FY2016 | FY2017 | ||
| Total revenue | 313.0 | 138.4 | 26.2 | 2,639.5 | 4,168.2 | |
| Total expenses | 308.6 | 136.2 | 37.7 | 2,526.1 | 3,650.2 | |
| Profit after tax | 4.4 | 2.2 | 11.4 | 113.4 | 517.9 | |
Objects of the Issue
Company intend to utilize the proceeds from this public issue towards the following objects:
1. Purchase of new plant and machinery and upgradation of our existing plant and machinery.
2. Civil Construction work at existing manufacturing unit.
3. To obtain registration of European Union GMP & Pharmaceutical Inspection Co-operation Scheme certificate.
4. Working Capital requirements.
5. General Corporate Purpose.
Beta Drugs IPO Prospectus
Company Contact Information
Beta Drugs Limited
Village Nandpur Baddi 17410
Phone: 01795-236196
Email: info@betadrugslimited.com
Website: http://betadrugslimited.com/
Beta Drugs IPO Registrar
Link Intime India Private Ltd
Phone: +91-22-4918 6270
Email:
Website: https://linkintime.co.in/ws
Beta Drugs IPO Lead Manager(s)
- Pantomath Capital Advisors Pvt Ltd (Past IPO Performance)
